Now Reading:
Aktis Oncology’s AKY-1189 Shows Potential in Targeting Cancers
Full Article 40 second read

Aktis Oncology’s AKY-1189 Shows Potential in Targeting Cancers

By Daniella Parra

Aktis Oncology said AKY-1189 is showing promise to treat cancers such as metastatic urothelial carcinoma, breast, lung, colorectal and cervical cancers.

The company said data from an oral plenary and two posters highlighted significant tumor uptake and favorable biodistribution, demonstrating AKY-1189’s potential effectiveness and safety.

“As the first therapeutic product candidate discovered from our novel miniprotein radioconjugate platform, AKY-1189 data suggest that we can achieve a favorable clinical profile and opens a new path forward in the field of radiopharmaceuticals,” said Matthew Roden, PhD, President and Chief Executive Officer of Aktis Oncology. “We look forward to advancing this promising product candidate through therapeutic clinical studies.”

Contact:

Editor@executives-edge.com

Leave a Reply

Your email address will not be published. Required fields are marked *

Input your search keywords and press Enter.